1. Robotic natural orifice specimen extraction surgery versus traditional robotic-assisted surgery (NOTR) for patients with colorectal cancer: a study protocol for a randomized controlled trial
- Author
-
Penghui He, Fangfang Zheng, Dongning Liu, Weiquan Zhu, Rui Luo, and Haobo Zhang
- Subjects
medicine.medical_specialty ,Natural orifice extraction surgery ,Colorectal cancer ,Medicine (miscellaneous) ,Natural orifice ,law.invention ,03 medical and health sciences ,Study Protocol ,0302 clinical medicine ,Primary outcome ,Randomized controlled trial ,Robotic Surgical Procedures ,law ,medicine ,Humans ,Minimally Invasive Surgical Procedures ,Multicenter Studies as Topic ,Pharmacology (medical) ,Robotic surgery ,Prospective Studies ,Randomized Controlled Trials as Topic ,Protocol (science) ,lcsh:R5-920 ,business.industry ,technology, industry, and agriculture ,medicine.disease ,Robotic assisted surgery ,Surgery ,Treatment Outcome ,Research Design ,030220 oncology & carcinogenesis ,Invasive surgery ,030211 gastroenterology & hepatology ,Laparoscopy ,business ,Colorectal Neoplasms ,lcsh:Medicine (General) ,human activities - Abstract
Background Natural orifice specimen extraction surgery for colorectal cancer has been introduced in order to reduce the abdominal incision, demonstrating major development potential in minimally invasive surgery. We are conducting this randomized controlled trial to assess whether robotic NOSES is non-inferior to traditional robotic-assisted surgery for patients with colorectal cancer in terms of primary and secondary outcomes. Method/design Accordingly, a prospective, open-label, randomized controlled, parallel-group, multicenter, and non-inferiority trial will be conducted to discuss the safety and efficacy of robotic natural orifice extraction surgery compared to traditional robotic-assisted surgery. Here, 550 estimated participants will be enrolled to have 80% power to detect differences with a one-sided significance level of 0.025 in consideration of the non-inferiority margin of 10%. The primary outcome is the incidence of surgical complications, which will be classified using the Clavien-Dindo system. Discussion This trial is expected to reveal whether robotic NOSES is non-inferior to traditional robotic-assisted surgery, which is of great significance in regard to the development of robotic NOSES for patients with colorectal cancer in the minimally invasive era. Furthermore, robotic NOSES is expected to exhibit superiority to traditional robotic-assisted surgery in terms of both primary and secondary outcomes. Trial registration ClinicalTrials.govNCT04230772. Registered on January 15, 2020.
- Published
- 2021